Company Profile

  1. You are here:    Home
  2. Search Databases
  3. Search Company Registry
  4. Company Profile

Oncofactor Corporation
Profile last edited on: 4/29/19      CAGE: 6XVG5      UEI:

Business Identifier: Next generation of oncology therapeutics
Year Founded
2011
First Award
2014
Latest Award
2014
Program Status
Inactive
Popularity Index

Edit Company Profile

Is this YOUR Company?
Ensure accuracy and completeness of YOUR Company Profile by completing the brief Survey Instrument attached
Do you know about this Awardees?
Let us encourage you to provide any data which would enhance the completeness of this firm's profile.
  Explanation Edit

Location Information

1616 Eastlake Avenue East Suite 200
Seattle, WA 98102
   (206) 957-7300
   N/A
   N/A
Location: Single
Congr. District: 07
County: King

Public Profile

Oncofactor Corporation had been working on development of cancer therapeutics that disrupt signaling pathways between tumors and the immune system. The firm's oncology platform was designed to identify and target immune modulating proteins differentially expressed by cancer cells. Conventional cancer therapies are either toxic to rapidly dividing cells or target molecular mechanisms which play critical roles in tumorigenesis. The company had been addressing the development of cancer therapeutics that disrupt signaling pathways between tumors and the immune system. It would seem that the firm closed up shop some time before 2015 - their former Vice President having joined Celgene in a senior capacity in mid-2014

Extent of SBIR involvement

User Avatar
Phase I Awards
1
Phase II Awards
0
Conversion Rate
0.00%
Phase I Dollars
$220,191
Phase II Dollars
$0
Total Awarded
$220,191

Synopsis: Awardee Business Condition

Employee Range
5-9
Revenue Range
.5M-1M
VC funded?
Yes
Public/Private
Privately Held
Stock Info
----
IP Holdings
1-4

Awards Distribution by Agency

Most Recent SBIR Projects
Year Phase Agency Total Amount
2014 1 NIH $220,191
Project Title: Treatment of non-small cell lung cancer with a CCL14 monoclonal antibody

Key People / Management

  Sarah Ellen Warren -- Director of Discovery & Validation

  Teresa Foy -- former Chief Scientific Officer

  Carl Weissman -- Executive Director

Company News

May 24 2011
Accelerator's New Startup, Oncofactor, Seeks to Spark Immune System Fight Against Cancer